Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - darifenacin hydrobromide, quantity: 17.857 mg (equivalent: darifenacin, qty 15 mg) - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; calcium hydrogen phosphate; titanium dioxide; purified talc; macrogol 4000; iron oxide yellow; iron oxide red - enablex prolonged-release tablets are indicated for the treatment of overactive bladder, with the symptoms of urgency, urge urinary incontinence or frequency of micturition.

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - estradiol valerate (in brown tablet); estradiol valerate (in white tablet); norgestrel (in brown tablet) - tablet, sugar coated - 2 mg - estradiol valerate (in brown tablet) 2 mg; estradiol valerate (in white tablet) 2 mg; norgestrel (in brown tablet) 0.5 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - darifenacin hydrobromide, quantity: 8.929 mg (equivalent: darifenacin, qty 7.5 mg) - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; calcium hydrogen phosphate; titanium dioxide; purified talc; macrogol 4000 - enablex prolonged-release tablets are indicated for the treatment of overactive bladder, with the symptoms of urgency, urge urinary incontinence or frequency of micturition.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - varenicline tartrate, quantity: 1.71 mg (equivalent: varenicline, qty 1 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; hypromellose; triacetin; hyprolose; titanium dioxide; indigo carmine aluminium lake; sodium stearylfumarate; croscarmellose sodium - varenicline tablets are indicated as an aid to smoking cessation in adults over the age of 18 years.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - methylprednisolone, quantity: 4 mg - tablet - excipient ingredients: gelatin; maize starch; magnesium stearate; purified talc; lactose monohydrate - yonsa mpred is indicated for the treatment of patients with: newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt), or; patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mcrpc) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (adt) or; patients with mcrpc who have received prior chemotherapy containing a taxane.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الادوية العربي - the arab drug store p.s.c - linagliptin 5 milligram/1 tablet, empagliflozin 25 milligram/1 tablet - 5 milligram/1 tablet, 25 milligram/1 tablet

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الادوية العربي - the arab drug store p.s.c - linagliptin 5 milligram/1 tablet, empagliflozin 10 milligram/1 tablet - 5 milligram/1 tablet, 10 milligram/1 tablet

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - (tablet core, product) drospirenone; (tablet core, product) ethinylestradiol betadex clathrate - tablet, film coated - 3.000 mg - (tablet core, product) drospirenone 3.000 mg; (tablet core, product) ethinylestradiol betadex clathrate 0.020 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - carbamazepine, quantity: 200 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; purified talc; titanium dioxide; magnesium stearate; acrylates copolymer; peg-40 hydrogenated castor oil; hypromellose; colloidal anhydrous silica; carmellose sodium; iron oxide yellow; iron oxide red; purified water; ethylcellulose; sodium lauryl sulfate; cetyl alcohol; hydrogen peroxide; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - 1. epilepsy: complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalisation; generalised tonic-clonic seizures; mixed seizure patterns incorporating the above. tegretol is suitable for monotherapy and combination therapy. tegretol is usually not effective in absence seizures, atonic seizures and myoclonic seizures and should not be used for status epilepticus (see "precautions"). 2. trigeminal neuralgia: for relief of pain in idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis; and in idiopathic glossopharyngeal neuralgia. (tegretol is not a simple analgesic and is not intended for trivial facial pain or headache). 3. mania and bipolar affective disorders: treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - carbamazepine, quantity: 400 mg - tablet, modified release - excipient ingredients: purified talc; microcrystalline cellulose; titanium dioxide; hypromellose; acrylates copolymer; peg-40 hydrogenated castor oil; iron oxide yellow; colloidal anhydrous silica; magnesium stearate; carmellose sodium; iron oxide red; purified water; ethylcellulose; sodium lauryl sulfate; cetyl alcohol; hydrogen peroxide; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - 1. epilepsy: complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalisation; generalised tonic-clonic seizures; mixed seizure patterns incorporating the above. tegretol is suitable for monotherapy and combination therapy. tegretol is usually not effective in absence seizures, atonic seizures and myoclonic seizures and should not be used for status epilepticus (see "precautions"). 2. trigeminal neuralgia: for relief of pain in idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis; and in idiopathic glossopharyngeal neuralgia. (tegretol is not a simple analgesic and is not intended for trivial facial pain or headache). 3. mania and bipolar affective disorders: treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.